Publications by authors named "O Gray"

Background: Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our aim was to investigate the potential effect of DMT on disability worsening among patients with PPMS stratified by different disability trajectories.

View Article and Find Full Text PDF
Article Synopsis
  • * Machine learning models were applied to predict confirmed disability progression after two years, achieving a ROC-AUC score of 0.71, indicating moderate accuracy, while historical disability was found to be a stronger predictor than treatment or relapse history.
  • * The research followed strict guidelines and made its coding accessible for others to facilitate future benchmarking in predicting disability progression in MS patients.
View Article and Find Full Text PDF

Background: The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset.

Methods: A multi-centre longitudinal study with 8,771 participants from MSBase was conducted.

View Article and Find Full Text PDF
Article Synopsis
  • Non-specific immunosuppressants (NSIS) are still widely used for treating multiple sclerosis (MS) despite safety concerns, particularly in resource-limited areas.
  • The study analyzed MSBase registry data to compare treatment outcomes of adults with relapsing-remitting MS (RRMS) using dimethyl fumarate (DMF) versus NSIS between January 2014 and April 2022.
  • Results showed that while annualized relapse rates were similar, DMF led to longer times before treatment discontinuation and confirmed disability progression, supporting its use over NSIS for RRMS patients.
View Article and Find Full Text PDF

Background: It remains unclear whether routine cerebrospinal fluid (CSF) parameters can serve as predictors of multiple sclerosis (MS) disease course.

Methods: This large-scale cohort study included persons with MS with CSF data documented in the MSBase registry. CSF parameters to predict time to reach confirmed Expanded Disability Status Scale (EDSS) scores 4, 6 and 7 and annualised relapse rate in the first 2 years after diagnosis (ARR2) were assessed using (cox) regression analysis.

View Article and Find Full Text PDF